3-Hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitors (statins), atherosclerosis and coronary syndromes

Atherosclerosis

Volumn 175, Issue 1, 2004, Pages 1-5

  Blum, Arnon ^a   Simsolo, Claudia ^a   Hasin, Yonathan ^a  

^a Poriya Hospital   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE SYNTHASE; PRAVASTATIN; SIMVASTATIN;

ACUTE HEART INFARCTION; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; ISCHEMIC HEART DISEASE; META ANALYSIS; MORBIDITY; MORTALITY; POSTOPERATIVE COMPLICATION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; RESTENOSIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; STEM CELL; STROKE; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY; UPREGULATION; VASCULAR ENDOTHELIUM;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; CORONARY RESTENOSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MYOCARDIAL ISCHEMIA;

EID: 2942525141     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2003.12.024     Document Type: Review

References (17)

1. Tonkin A.M. Clinical relevance of statins: their role in secondary prevention. Atheroscler. Suppl. 2(1):2001;21-25
2. Pignone M., Phillips C., Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomized trials. BMJ. 21:321(7267):2000;983-986
3. Stenestrand U., Wallentin L. Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 285(4):2001;430-436
4. Mulder H.J., Bal E.T., Jukema J.W., Zwinderman A.H., Schalij M.J., van Boven A.J., et al. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial). Am. J. Cardiol. 86(7):2000;742-746
5. Walter D.H., Schachinger V., Elsner M., Mach S., Auch-Schwelk W., Zeiher A.M. Effect of statin therapy on restenosis after coronary stent implantation. Am. J. Cardiol. 85(8):2000;962-968
6. Schartl M., Bocksch W., Koschyk D.H., Voelker W., Karsch K.R., Kreuzer J., et al. Use of intravascular ultrasound to compare effects of different strategies of lipid lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation. 104:2001;387-392
7. Holm T., Andreassen A.K., Ueland T., Kjekshus J., Froland S.S., Kjekshus E., et al. Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am. J. Cardiol. 87(6):2001;815-818
8. Albert M.A., Danielson E., Rifai N., Ridker P.M. PRINCE investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 286(1):2001;64-70
9. Tsunekawa T., Hayashi T., Kano H., Sumi D., Matsui-Hirai H., Thakur N.K., et al. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation. 104:2001;376-379
10. Plana J.C., Jones P.H. The use of statins in acute coronary syndromes: the mechanisms behind the outcomes. Curr. Atheroscler. Rep. 3(5):2001;355-364
11. Jackson G. The role of statins in acute coronary syndromes: managing unmet need. Int. J. Clin. Pract. 54(7):2000;445-449
12. Murphy R.T., Foley J.B., Mulvihill N., Crean P., Walsh M.J. Impact of preexisting statin use on adhesion molecule expression in patients presenting with acute coronary syndromes. Am. J. Cardiol. 87(4):2001;446-448
13. Thompson P.L. Clinical relevance of statins: instituting treatment early in acute coronary syndrome patients. Atheroscler. Suppl. 2(1):2001;15-19
14. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 6(12):2000;1399-1402
15. Vasa M., Fichtlscherer S., Adler K., Aicher A., Martin H., Zeiher A.M., et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 103:2001;2885-2890
16. Laufs U., La Fata V., Plutzky J., Liao K.L. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 97:1998;1129-1135
17. Undas A., Brummel K.E., Musial J., Mann K.G., Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 103:2001;2248-2253